Current Evidence of sacubitril/valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction

Abstract

Heart failure (HF) is one of the most common reasons for hospital admission in western countries. The measurement of the left ventricular ejection fraction is essential for the classification of HF and deciding on HF treatment. The treatment of HF has been improved in both diagnostic and therapeutic fields over the past two decades. The angiotensin receptor-neprilysin inhibitor decreased the cardiovascular mortality in patients with chronic HF with reduced ejection fraction. Sacubitril/valsartan (LCZ696) improves the imbalance between the renin-angiotensin-aldosterone and natriuretic peptide systems. We present the clinical efficacy, real-world experience, safety and tolerability, the relevance of etiology of cardiomyopathy, and gender differences and regulatory affairs of LCZ696 in the treatment of patients with HF with reduced ejection fraction.

Keywords:

• angiotensin-neprilysin inhibition
• ARNI
• heart failure
• HFrEF
• LCZ696
• life-threatening arrhythmia
• natriuretic peptide
• outcome
• sacubitril/valsartan

Disclaimer

All authors have participated in the work and have reviewed and agree with the content of the article.

Financial & competing interests disclosure

All authors are members of German Center of Cardiovascular Research, Heidelberg–Mannheim and supervising LCZ696 register of Faculty Medicine Mannheim, Heidelberg University. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.